CC™ Perspective
Saturday
Friday
ADAM - The Origin of Black People
CC™ Perspective
Thursday
Fascinating African Cultures To Explore
CC™ Perspective
Tuesday
Bloomberg makes $600 million contribution to Howard University and 3 other top Black medical schools
CC™ NewsDay
Michael Bloomberg's organization Bloomberg Philanthropies announced a $600 million gift to the endowments of four historically Black medical schools.
Bloomberg, the former New York City mayor and the billionaire founder of Bloomberg LP, made the announcement Tuesday in New York at the annual convention of the National Medical Association, an organization that advocates for African American physicians.
"This gift will empower new generations of Black doctors to create a healthier and more equitable future for our country," Bloomberg said in a statement.
Black Americans fare worse in measures of health compared with white Americans, an Associated Press series reported last year. Experts believe increasing the representation among doctors is one solution that could disrupt these long-standing inequities. In 2022, only 6% of U.S. physicians were Black, even though Black Americans represent 13% of the population.
The gifts are among the largest private donations to any historically Black college or university, with $175 million each going to Howard University College of Medicine, Meharry Medical College and Morehouse School of Medicine. Charles Drew University of Medicine & Science will receive $75 million. Xavier University of Louisiana, which is opening a new medical school, will also receive a $5 million grant.
The donations will more than double the size of three of the medical schools' endowments, Bloomberg Philanthropies said.
The commitment follows a $1 billion pledge Bloomberg made in July to Johns Hopkins University that will mean most medical students there will no longer pay tuition. The four historically Black medical schools are still deciding with Bloomberg Philanthropies how the latest gifts to their endowments will be used, said Garnesha Ezediaro, who leads Bloomberg Philanthropies' Greenwood Initiative.
The initiative, named after the community that was destroyed during the race massacre in Tulsa, Oklahoma more than 100 years ago, was initially part of Bloomberg's campaign as a Democratic candidate for president in 2020. After he withdrew from the race, he asked his philanthropy to pursue efforts to reduce the racial wealth gap and so far, it has committed $896 million, including this latest gift to the medical schools, Ezediaro said.
In 2020, Bloomberg granted the same medicals schools a total of $100 million that mostly went to reducing the debt load of enrolled students, who schools said were in serious danger of not continuing because of the financial burdens compounded by the COVID-19 pandemic.
"When we talked about helping to secure and support the next generation of Black doctors, we meant that literally," Ezediaro said.
Valerie Montgomery Rice, president of Morehouse School of Medicine, said that gift relieved $100,000 on average in debt for enrolled medical students. She said the gift has helped her school significantly increase its fundraising.
"But our endowment and the size of our endowment has continued to be a challenge, and we've been very vocal about that. And he heard us," she said of Bloomberg and the latest donation.
Previous largest single donation to an HBCU
In January, the Lilly Endowment gave $100 million to The United Negro College Fund toward a pooled endowment fund for 37 HBCUs. That same month, Spelman College, a historically Black women's college in Atlanta, received a $100 million donation from Ronda Stryker and her husband, William Johnston, chairman of Greenleaf Trust.
Denise Smith, deputy director of higher education policy and a senior fellow at The Century Foundation, said the gift to Spelman was the largest single donation to an HBCU that she was aware of, speaking before Bloomberg Philanthropies announcement Tuesday.
Smith authored a 2021 report on the financial disparities between HBCUs and other higher education institutions, including the failure of many states to fulfill their promises to fund historically Black land grant schools. As a result, she said philanthropic gifts have played an important role in sustaining HBCUs, and pointed to the billionaire philanthropist and author MacKenzie Scott's gifts to HBCUs in 2020 and 2021 as setting off a new chain reaction of support from other large donors.
"Donations that have followed are the type of momentum and support that institutions need in this moment," Smith said.
Dr. Yolanda Lawson, president of the National Medical Association, said she felt "relief," when she heard about the gifts to the four medical schools. With the Supreme Court's decision striking down affirmative action last year and attacks on programs meant to support inclusion and equity at schools, she anticipates that the four schools will play an even larger role in training and increasing the number of Black physicians.
"This opportunity and this investment affects not only just those four institutions, but that affects our country. It affects the nation's health," she said.
Utibe Essien, a physician and assistant professor at the David Geffen School of Medicine at UCLA, who researches racial disparities in treatment, said more investment and investment in earlier educational support before high school and college would make a difference in the number of Black students who decide to pursue medicine.
He said he also believes the Supreme Court decision on affirmative action and the backlash against efforts to rectify historic discrimination and racial inequities does have an impact on student choices.
"It's hard for some of the trainees who are thinking about going into this space to see some of that backlash and pursue it," he said. "Again, I think we get into this spiral where in five to 10 years we're going to see a concerning drop in the numbers of diverse people in our field."
Source: The Associated Press - AP
Monday
Discovery: Scientists ‘switch off’ autism symptoms using $3 epilepsy drug
CC™ HealthWatch
By Adriana Diaz
Scientists are reporting a breakthrough discovery: A $3-per-pill epilepsy drug may be used to “switch off” autism symptoms in mice, according to a new peer-reviewed study published Tuesday in Molecular Psychiatry journal.
Autism spectrum disorder is a complex developmental condition that impacts how an estimated 5.4 million (2.2% of) adults — and one in 44 children — in the United States perceives and socializes with others. It is often accompanied by abnormalities such as epilepsy or hyperactivity, according to Centers for Disease Control and Prevention data.
A team of experts at Germany’s Hector Institute for Translational Brain Researchfound that the medication lamotrigine — an anti-seizure drug first approved for use in the US in 1994 — was able to curb behavioral and social problems linked to the disorder.
Now, their findings are being hyped as the closest thing yet to a potential cure for humans.
“Apparently, drug treatment in adulthood can alleviate brain cell dysfunction and thus counteract the behavioral abnormalities typical of autism,” lead researcher and cellular biologist Moritz Mall said in a statement. “[This occurs] even after the absence of MYT1L has already impaired brain development during the developmental phase of the organism.”
Lamotrigine, which is sold under the brand name Lamictal, among others, is a medication used to treat epilepsy and stabilize mood in those who suffer from bipolar disorder.
The drug, which typically sells for just under $3 per pill, works by reversing changes to brain cells caused by a genetic mutation.
Scientists have spent years searching forthe molecular abnormalities that contribute to ASD and have identified MYT1L protein as one that plays a role in various neuronal diseases.
The protein is a so-called transcription factor produced by almost all the nerve cells in the body that decides which genes are or are not active in the cell. It also “protects the identity of nerve cells by suppressing other developmental pathways that program a cell towards muscle or connective tissue.”
Mutations of the protein have previously been linked to other neurological diseases and brain malformations.
To test impact of the protein on autism symptoms, researchers at HITBR genetically “switched off” MYT1L in mice and human nerve cells. They found that this led to electrophysiological hyperactivation in the mouse and human neurons impairing nerve function.
The mice lacking MYT1L suffered from brain abnormalities and showed several behavioral changes typical to ASD, such as social deficits or hyperactivity.
Researchers noted that the most “striking” reaction was the discovery that the MYT1L-deficient neurons produced extra sodium channels that are typically restricted to cells in the heart muscle.
These proteins are critical for electrical conductivity and cell function as they allow sodium ions to travel through the cell membrane. Nerve cells that overproduce these sodium channels can result in electrophysiological hyperactivation — a common symptom of autism.
“When MYT1L-deficient nerve cells were treated with lamotrigine, their electrophysiological activity returned to normal. In mice, the drug was even able to curb ASD-associated behaviors such as hyperactivity,” the statement continued.
These promising results come as autism rates have skyrocketed in the NYC metro area. Autism diagnoses have tripled in the New York-New Jersey metro area: from 1% of the population in 2000 to 3% in 2016.
It is believed that part of the drastic increase of these diagnoses is due to the growing number of diagnoses of children without intellectual disabilities, which are therefore less likely to have been identified previously.
But earlier, more accurate diagnoses don’t completely explain the upward trend, which was based on estimates from the CDC. Experts have warned that the growing trend of women giving birth later in life may be partly responsible for the rise.
Meanwhile, clinical human trials studying lamotrigine’s impact on MYT1L are being planned — and while the research is currently limited to mice, the results are promising, researchers stressed.
SOURCE: NYP